
RKVTF
Healthcare · Biotechnology · $3.1M market cap
$0.12530.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2026
EPS trend, 90 days to now
Beat estimates in 0 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 28, 2025 | Before the open | — | -0.01 | — |
| Nov 25, 2024 | Before the open | — | -0.01 | — |
| Aug 30, 2024 | After the close | — | -0.01 | — |
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit…